What can we learn about schizophrenia from studying the human model, drug-induced psychosis?

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 162, Issue 7, 2013, Pages 661-670

  Murray, Robin M ^a   Paparelli, Alessandra ^a   Morrison, Paul D ^a   Marconi, Arianna ^a   Di Forti, Marta ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amphetamines; LSD; Psychosis; Schizophrenia; Substances

Indexed keywords

CANNABIS; DOPAMINE; DYSBINDIN; ENDOCANNABINOID; KETAMINE; LYSERGIDE; METHAMPHETAMINE; MITOCHONDRIAL PROTEIN; MU OPIATE RECEPTOR; N,N DIMETHYLTRYPTAMINE;

ADAPTATION; ARTICLE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; NEUROPHARMACOLOGY; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMPHETAMINES; LSD; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCES;

ENDOCANNABINOIDS; GLUTAMATES; HUMANS; MODELS, BIOLOGICAL; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; SEROTONIN;

EID: 84885781228     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32177     Document Type: Article

References (143)

1. Adermark L, Talani G, Lovinger DM. 2009. Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 29(1):32.
2. Anden NE, Corrodi H, Fuxe K, Hokfelt T. 1968. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Br J Pharmacol 34:1-7.
3. Andreasson S, Allebeck P, Engstrom A, Rydberg U. 1987. Cannabis and Schizophrenia: A longitudinal study of Swedish conscripts. Lancet 26:1483-1486.
4. Angrist B, Sathananthan G, Wilk S, Gershon S. 1974. Amphetamine psychosis: Behavioural and biochemical aspects. J Psychiatr Rs 11:13-23.
5. Anis NA, Berry SC, Burton NR, Lodge D. 1983. The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-d-aspartate. Br J Pharmacol 79:565-575.
6. Arora RC, Meltzer HY. 1991. Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 85:19-29.
7. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. 2002. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 325:1212-1213.
8. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. 2009. " Spice" and other herbal blends: Harmless incense or cannabinoid designer drugs? J Mass Spectrom 44(5):832-837.
9. Bajaj N, Mullen D, Wylie S. 2010. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect: Dependence and psychosis with 4-methylmethcathinone (mephedrone) use BMJ Case Reports.
10. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, Pernet DE, Kirkbride JB, Murray GK, Bullmore ET, Jones PB. 2007. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190:515-520.
11. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM. 2011. Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 11:1462-1468.
12. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. 2009. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3):764-774.
13. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. 2006. Modeling sensitization to stimulants in humans. An [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 63:1386-1395.
14. Bosi D, Hallak J, Dursun S, Deakin J, Zuardi A. 2003. Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. J Psychopharmacol 17A:55.
15. Chevaleyre V, Takahashi KA, Castillo PE. 2006. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37-76.
16. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS. 2009. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34(3):759-766.
17. Bousman CA, Glatt SJ, Everall IP, Tsuang MT. 2009. Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. Am J Med Genet 150B:1025-1049.
18. Breakey WR, Goodell H, Lorenz PC, McHugh PR. 1974. Hallucinogenic drugs as precipitants of schizophrenia. Psychol Med 4:255-261.
19. Broome MR, Woolley JB, Tabraham P, Johns LC, Bramon E, Murray GK, Pariante C, McGuire PK, Murray RM. 2005. What causes the onset of psychosis? Schizophr Res 79:23-34.
20. Calabresi P, Picconi B, Tozzi A, Di Filippo M. 2007. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30(5):211-219.
21. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. 2012. Methamphetamine use and schizophrenia: A population-based cohort study in California. Arch Gen Psychiatry 169:389-396.
22. Carlsson A, Lindqvist M. 1963. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144.
23. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. 2005. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol Psychiatry 57:1117-1127.
24. 1 receptors. Eur J Neurosci 25(6):1631-1640.
25. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, Chiang YL, Ree SC, Lee CH, Murry RM. 2003. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med 33:1407--1414.
26. Chiang YC, Chen JC. 2007. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. J Neurochem 103(6):2505-2517.
27. Collins VJ, Gorospe CA, Rovenstine EA. 1960. Intravenous nonbarbiturate, non narcotic analgesics: Preliminary studies. I Cyclohexylamines Anesth Analg 39:303-306.
28. Connell PH. 1958. Amphetamine Psychosis. Maudsley monographs. No. 5. London: Oxford University Press.
29. Corbille AG, Valjent E, Marsicano G, Ledent C, Lutz B, Herve D, Girault JA. 2007. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 27(26):6937-6947.
30. Deakin JF, Simpson DC. 1997. A two-process theory of schizophrenia: Evidence from studies in post-mortem brain. J Psych Res 31(2):277-295.
31. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK. 2013. Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. Biological psychiatry.
32. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM. 2012. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72:811-816.
33. Di Forti M, Lappin JM, Murray RM. 2007. Risk factors for schizophrenia-All roads lead to dopamine. Eur Neuropsychopharmacol 17S:101-107.
34. Di Forti M, Morrison PD, Butt A, Murray RM. 2007. Cannabis use and psychiatric and cognitive disorders: The chicken or the egg? Curr Opin Psychiatry 20:228-234.
35. Di Forti M, Murray RM. 2005. Cannabis consumption and risk of developing schizophrenia: Myth or reality? Epidemiol Psichiatr Soc 14(4):184-187.
36. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Reis Marques T, Handley R, Aas M, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM. 2009. Use of high potency cannabis is associated with a greater risk of psychosis. Br J Psychiatry 195:488-491.
37. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. 2004. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29(8):1558-1572.
38. EMCDDA European Monitoring Centre for Drugs and Drug Addiction. 2009. Annual report: The state of the drugs problem in Europe.
39. EMCDDA European Monitoring Centre for Drugs and Drug Addiction. 2010. Annual report: The state of the drugs problem in Europe.
40. Every-Palmer S. 2011. Synthetic cannabinoid JWH-018 and psychosis; an exploratory study. Drug Alcohol Depend 117:152-157.
41. Fergusson DM, Horwood LJ, Swain-Campbell NR. 2003. Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15-21.
42. Fergusson DM, Poulton R, Smith PF, Boden JM. 2006. Cannabis and psychosis. BMJ 332:172-175.
43. Franzen F, Gross H. 1965. Tryptamine, N, N-dimethyltryptamine, N, N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine. Nature 1052.
44. Freiman I, Anton A, Monyer H, Urbanski MJ, Szabo B. 2006. Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol 575(3):789-806.
45. Gerdeman GL, Ronesi J, Lovinger DM. 2002. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5(5):446-451.
46. Gillin JC, Kaplan J, Stillman R, Wyall RJ. 1976. The psychedelic model of schizophrenia: The case of N, N-dimethyltryptamine. Am J Psychiatry 133:203-208.
47. Glennon RA, Rosecrans JA, Young R. 1983. Drug-induced discrimination: A description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289-340.
48. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. 1999. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2(4):358-363.
49. Glenthøj BY, Hemmingsen R. 1997. Dopaminergic Sensitization: Implications for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 21:22-46.
50. Gonzalez-Maeso J, Sealfon S. 2009. Psychedelics and schizophrenia. Trends Neurosci 32(4):225-232.
51. Gottesman II, Shields J. 1971. Editors of "man, mind and heredity: The selected papers of Eliot Slater on psychiatry and genetics." Baltimore and London: John Hopkins Press. 405 p.
52. Graybiel AM. 2005. The basal ganglia: Learning new tricks and loving it. Curr Opin Neurobiol 15(6):638-644.
53. Grelotti DJ, Kanayama G, Pope HG. 2010. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. American Journal of Psychiatry 167(1):17-23.
54. Henquet C, Murray RM, Linszen D, van Os J. 2005. The environment and schizophrenia: The role of cannabis use. Schizophr Bull 31:608-612.
55. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1991. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11(2):563-583.
56. Hillebrand J, Olsewski D, Sedefow R. 2010. Legal highs on the Internet. Subst Use Misuse 45:330-340.
57. Hofmann A. 1980. LSD-My problem child. New York: McGraw-Hill.
58. Houk JC, Bastianen C, Fansler D, Fishbach A, Fraser D, Reber PJ, Reber PJ, Roy SA, Simo LS. 2007. Action selection and refinement in subcortical loops through basal ganglia and cerebellum. Philos Trans R Soc Lond B Biol Sci 362(1485):1573-1583.
59. 1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58(4):322-328.
60. Iyo M, Sekine Y, Mori N. 2004. Neuromechanism of developing methamphetamine psychosis: A neuroimaging study. Ann NY Acad Sci 1025:288-329.
61. Javitt DC, Zukin SR. 1990. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
62. Joyce JN, Shane A, Lexow N, Winokur A, Casanova M, Kleinmann JE. 1993. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336.
63. Kassim S, Croucher R. 2006. Khat chewing amongst UK resident male Yemeni adults: An explanatory study. Internat Dental J 56:97-101.
64. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. 1980. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382.
65. Kreitzer AC, Malenka RC. 2005. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25(45):10537-10545.
66. Kreitzer AC, Malenka RC. 2007. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445(7128):643-647.
67. Kreitzer AC, Malenka RC. 2008. Striatal plasticity and basal ganglia circuit function. Neuron 60(4):543-554.
68. Kuepper R, Van Os J. 2012. Data presented at the Joint EU-GEI and EPA meeting in Maastricht June.
69. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240.
70. Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA. 2005. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol 15(1):31-37.
71. Leweke FM, Koethe D, Pahlisch F, Schreiber D, Gerth CW, Nolden BM, Piomelli D. 2009. S39-02 Antipsychotic effects of cannabidiol. European Psychiatry 24:S207.
72. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. 2000. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 66(1):175-181.
73. Lieberman JA, Kane JM, Alvir J. 1987. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415-433.
74. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. 1998. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117.
75. Long LE, Malone DT, Taylor DA. 2006. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31(4):795-803.
76. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R. 1959. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 81:363-369.
77. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. 1962. Model psychoses and schizophrenia. Am J Psychiatry 119(1):61-67.
78. Lupica CR, Riegel AC. 2005. Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48(8):1105-1116.
79. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. 2012. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychological medicine 42(06):1321-1328.
80. McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. 2013. Dose-Related Psychotic Symptoms in Chronic Methamphetamine UsersEvidence From a Prospective Longitudinal StudyMethamphetamine Use and Psychosis. JAMA psychiatry 70(3):319-324.
81. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
82. Matyas F, Urban GM, Watanabe M, Mackie K, Zimmer A, Freund TF, Katona I. 2008. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54(1):95-107.
83. McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR, Alati R, Williams GM, Bor W, Najman JM. 2010. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adult. Arch Gen Psychiatry 67(5):440-447.
84. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, et al. 2004. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24(47):10707-10715.
85. Meltzer HY, Arvanitis L, Bauer D, Rein W. 2004. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161(6):975-984.
86. 2 receptors in chronic schizophrenics. Biol Psychiatry 21:1407-1414.
87. Meltzer HY. 1999. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21S:106-115.
88. Murray RM, Lappin J, Di Forti M. 2008. Schizophrenia: From developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 18S:129-134.
89. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370:319-328.
90. Moreira FA, Guimaraes FS. 2005. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512(2-3):199-205.
91. Morgan CJA, Curran V. 2012. Ketamine use: A review. Addiction 107:27-38.
92. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM. 2009. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39(10):1607-1616.
93. Murray RM, Morrison P, Henquet C, Di Forti M. 2007. Cannabis, the mind and society: The hash realities. Nat Rev Neurosci 8:885-895.
94. Murray RM, Oon MCH, Rodnight R, Birley JLT, Smith A. 1979. Increased excretion of dimethyltryptamine and certain features of psychosis. A possible association. Arch Gen Psychiatry 36:644-664.
95. Narasimhachari N, Avalos J, Fujimori M, Himwich HE. 1972. Studies of drug-free schizophrenics and controls. Biol Psychiat 5:311-318.
96. Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. 2013. Substance-induced psychoses converting into schizophrenia: A register-based study of 18, 478 Finnish inpatient cases. J Clin Psychiatry 74:e94-e99.
97. Odenwald M, Neuner F, Schauer M, Elbert T, Catani C, Lingenfelder B, Hinkel H, Häfner H, Rockstroh B. 2005. Khat use as risk factor for psychotic disorders: A cross-sectional and case-control study in Somalia. BMC Med 12:3-5.
98. Osmond H, Smythies J. 1952. Schizophrenia: A new approach. J Ment Sci 98:309-315.
99. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. 2007. Activation of mGluR2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13:1102-1107.
100. Peleg-Raibstein D, Yee BJ, Hauser J. 2009. The amphetamine sensitization model of schizophrenia: Relevance beyond psychotic symptoms? Psychopharmacology 206:603-621.
101. Pertwee RG. 2008. The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacol 153(2):199-215.
102. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Abasalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC. 2006. Psychological effects of ketamine in healthy volunteers. Br J Psychiatry 189:173-179.
103. Potter DJ, Clark P, Brown MB. 2008. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forensic Sci 53(1):90-94.
104. Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg LH, Baare' W, Svarer C, Lublin H, Knudsen GM, Glenthoj B. 2010. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 67(1):9-16.
105. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. 2002. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99(12):8384-8388.
106. Rodriguez MA. 2007. A methodology for studying various interpretations of the N, N-dimethyltryptamine-induced alternate reality. J Sci Explor 21(1):67-84.
107. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. 1959. Cornparisons of Sernyl with other drugs. Arch Gen Psychiatry 1:651-656.
108. Seeman P, Tallerico T. 2005. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psych 10:877-883.
109. Shaw E, Woolley DW. 1956. Some serotonin-like activities of lysergic acid diethylamide. Science 124:121.
110. Shields J, Gottesman, II. 1971. Man, mind and heredity; selected papers of Eliot Slater on psychiatry and genetics. Baltimore and London: The Johns Hopkins Press.
111. Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. 2009. Prevalence of psychotic symptoms in substance users: A comparison across substances. Compr Psychiatry 50(3):245-250.
112. Stilo SA, Murray RM. 2010. The epidemiology of schizophrenia: Replacing dogma with knowledge. Dialogues Clin Neurosci 12(3):305-315.
113. Stokes PR, Egerton A, Watson B, Reid A, Breen G, Lingford-Hughes A, Nutt DJ, Mehta MA. 2010. Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage 52:1521-1527.
114. Strassman RJ. 1991. Human hallucinogenic drug research in the United States: A present-day case history and review of the process. J Psychoactive Drug 23:29-38.
115. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. 2009. Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48(1):186-190.
116. Szara S. 1956. Dimethyltryptamine: Its metabolism in man: the relation of its psychotic effect to serotonin metabolism. Experientia 12:441-442.
117. Szendrei K. 1980. The chemistry of khat. Bull Narc 32(3):5-35.
118. Tamminga CA, Holcomb HH. 2005. Phenotype of schizophrenia: A review and formulation. Mol Psychiatry 10:27-39.
119. Tatetsu S, Goto A, Fujiwara T. 1956. Psychostimulant toxicosis. Tokyo: Igakushoin.
120. Terra Sigillata.Scienceblogs.com. 2010. What's the buzz? Synthetic marijuana, K2, Spice, JWH-018. http://scienceblogs.com/terrasig/2010/02/k2_spice_jwh018_marijuana.php
121. Thiemann G, Di Marzo V, Molleman A, Hasenohrl RU. 2008a. The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacol Biochem Behav 89 (3):384-391.
122. 1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behav Brain Res 187(2):289-296.
123. Tsuang MT, Simpson JC, Kronfol Z. 1982. Subtypes of drug abuse with psychosis. Arch Gen Psychiatry 39:141-147.
124. Tulloch A, Frayn E, Craig KT, Nicholson TRJ. 2012. Khat use among Somali mental health service users in London. Soc Psychiatry Psychiatric Epidemiol 47:1649-1656.
125. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. 2007. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27(14):3663-3676.
126. UNODC, United Nations Office on Drugs and Crime. 2009. Patterns and trends of amphetamine-type stimulants and other drugs in easr and south-east asia (and neighbouring regions). Annual report.
127. Van Os J, Bak M, Hanssen M, Bij RV, de Graaf R, Verdoux H. 2002. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 156(4):319-327.
128. Van Os J, Rutten BP, Poulton R. 2008. Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull 34:1066-1082.
129. Van Os J, Kenis G, Rutten BPF. 2010. The environment and schizophrenia. Nature 468:203-2012.
130. Vardy MM, Kay SR. 1983. LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Arch Gen Psychiatry 40:877-883.
131. Van Rossum JM. 1967. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. Proceedings of the 5th Collegium Internationale Neuropsychopharmacologicum.
132. Van Winkel R, Kahn RS, Linszen DH, Van Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I. 2011. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. Arch Gen Psychiatry 68(2):148-157.
133. Volleinweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. 1997. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357-372.
134. Volleinweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897-3902.
135. Winstock AR, Marsden J, Mitcheson L. 2010. What should be done about mephedrone? Br Med J 340c:1605.
136. Yin HH, Knowlton BJ. 2006. The role of the basal ganglia in habit formation. Nat Rev 7(6):464-476.
137. Zammit LS, Allebeck P, Andreasson S, Lundberg I, Lewis G. 2002. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 325:1199-1212.
138. Zammit S, Owen MJ, Evans J, Heron J, Lewis G. 2011. Cannabis, COMT and psychotic experiences. The British Journal of Psychiatry 199(5):380-385.
139. Zuardi AW. 2006. History of cannabis as a medicine: A review. Rev Bras Psiquiatr 28(2):153-157.
140. Zuardi AW, Crippa J, Hallak J, Pinto J, Chagas M, Rodrigues G, et al. 2008. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 23(8):979-983.
141. Zuardi AW, Rodrigues JA, Cunha JM. 1991. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104(2):260-264.
142. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245-250.
143. 1 receptor agonist Org 26828 in healthy male volunteers. J Psychopharmacol 24(11):1689-1696.